Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for ...

Vertex Pharmaceuticals Inc. ( (VRTX)) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors. Vertex Pharmaceuticals Inc., a ...

Shares of Vertex Pharmaceuticals Inc. VRTX sank 0.67% to $474.91 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.05% to ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...